

ABSTRACTS

possess any significant anti-insulin activity on fat cells or adipose tissue but did have a weak lipolytic activity.

Wu, W. C.; Kengis, J.; Whalen, G. E.; Schulte, W. J.; Unger, G. F.; and Classen, M. (Depts. of Med., Surg., and Radiology, Med. Coll. of Wisc.; V.A. Center, Wood, Wisc., and Dept. of Med., Univ. Erlangen-Nuremberg, Erlangen, Germany): ENDOSCOPIC LOCALIZATION OF A DUODENAL WALL TUMOR IN ZOLLINGER-ELLISON SYNDROME. *Gastroenterology* 66:1237-39, 1974.

This is a short, interesting case report in which a patient with the Zollinger-Ellison syndrome is described. The origin of this syndrome was a tumor of the duodenal wall which was visualized by duodenoscopy. Histologically the tumor of the duodenal wall was an islet cell tumor. One retropancreatic lymph node showed metastatic tumor. The authors cite a 13 per cent incidence of the Zollinger-Ellison syndrome associated with duodenal wall tumors. Preoperative gastrin levels ranged from 300 to 900 pg. per milliliter. One month after surgery the gastrin levels returned to normal (62 pg. per milliliter). The authors suggest that duodenoscopy is indicated in all patients suspected of having the Zollinger-Ellison syndrome. F.G.B.

Young, E. A.; and Weser, E. (Dept. of Med., Univ. of Texas Med. Sch. at San Antonio, San Antonio, Texas): THE METABOLISM OF MALTOSE AFTER INTRAVENOUS INJECTION IN NORMAL AND

DIABETIC SUBJECTS. *J. Clin. Endocrinol. Metab.* 38:181-88, 1974.

Verbatim summary. The metabolism of intravenously administered maltose was compared with glucose in five fasting, adult, noninsulin-dependent, mildly diabetic subjects and contrasted with normal controls. After an intravenous injection of 25 gm. maltose containing 5 μ Ci maltose-U- 14 C or 25 gm. glucose containing either 5 μ Ci glucose-1- 14 C or glucose-U- 14 C, expired breath and urine were collected over a 6 hr. period. Blood samples obtained at 0, 15, 30, 60, 90, and 120 min. were assayed for insulin, total reducing substances and glucose.

Equal amounts of maltose and glucose were oxidized to 14 CO $_2$. The rate of oxidation for maltose was much slower with a peak 14 CO $_2$ excretion 100 min. later than for glucose. Diabetic subjects showed a delayed peak 14 CO $_2$ excretion after both sugars compared with normal subjects. Serum glucose concentration after maltose infusion remained less than 95 mg./10 ml. over the entire 2 hr. period, in contrast to the elevation of serum glucose following glucose administration. The increase in total serum reducing substances was similar after maltose and glucose administration. In normal and diabetic subjects, there was a significant rise in serum insulin after maltose injection, however, this increase was greater after glucose. Diabetic subjects showed an abnormal intravenous glucose tolerance test and higher serum insulin levels at 60, 90, and 120 min. after glucose infusion as compared to normal subjects. Circulating maltose may enter cells intact and subsequently be metabolized in a manner similar to glucose by both normal and diabetic subjects.

ORGANIZATION SECTION

TWENTY-SECOND POSTGRADUATE COURSE

Entitled "Diabetes in Review: Clinical Conference 1975," the Twenty-second Postgraduate Course of the American Diabetes Association will be presented at The Drake in Chicago, January 28-31. It will be presented under the direction of the Committee on Professional Education, of which Karl E. Sussman, M.D., Denver, is Chairman. Norbert Freinkel, M.D., Chicago, is Director of the Course, with Donald F. Steiner, M.D., and Theodore B. Schwartz, M.D., both of Chicago, as Co-Directors. The fee is \$100 for members of the Association and \$125 for nonmembers.

The program will be published in *DIABETES* and will be mailed separately to all members and Journal subscribers as well as to most internists, pediatricians, general practitioners and other interested physicians throughout the country.

SEVENTH ALLIED HEALTH POSTGRADUATE COURSE

The American Diabetes Association will hold its Seventh Allied Health Postgraduate Course in Diabetes at the Crown Center Hotel in Kansas City, Missouri, April 14-16, 1975.

THIRTY-FIFTH ANNUAL MEETING

The Americana Hotel in New York City will be the site of the Thirty-fifth Annual Meeting of the American Diabetes Association.

tion. June 15-17, 1975, are the dates for the Scientific Sessions.

NOVEMBER 15 DEADLINE FOR APPLICATIONS IN ESTABLISHED INVESTIGATOR PROGRAM

The Board of Directors of the American Diabetes Association, on the recommendation of the Committee on Research, has approved a program of five-year Established Investigatorships, to be initiated by the selection of two Investigators in the spring of 1975 for funding as of July 1. Additional Investigators will be selected each year until a total of fifteen per annum are supported.

Deadline: All nominations and supporting material should be sent to the Committee on Research, American Diabetes Association, Inc., and must be postmarked no later than November 15, 1974.

The Investigatorships will provide financial support for established scientists whose work is relevant to the general area of diabetes research. The Established Investigatorships will foster maximal research productivity for highly qualified individuals by providing the means to relieve them of excessive service, teaching or administrative responsibilities. The recipients of these awards are to be individuals of unusual research ability and originality who have made major contributions to the field of diabetes research regardless of age or present position. However, it is stipulated that at the time the award is made, the candidate must be actively engaged in research related directly or indirectly to diabetes. Individuals approaching retirement age will ordinarily not

ORGANIZATION SECTION

be considered as reasonable candidates except in cases of truly exceptional merit.

Terms of Award: The maximum contribution from the American Diabetes Association to the salary support of an Established Investigator is \$25,000 per year. Institutions remain responsible for fringe benefits and overhead. Institutions may supplement the salary of an awardee compatible with the institutional salary scale.

A grant of \$10,000 per annum is to be made available to each Established Investigator for laboratory and travel support. In addition, the Investigator may apply for other grants-in-aid from any organization, including the Association. The department and the institution in which the Investigator works will each receive \$1,000 annually.

Awardees are expected to devote a majority of effort to the achievement of the objectives of the Established Investigators. Their principal involvement must be with the actual conduct of research. They may, however, receive or provide research training and participate in teaching and other appropriate functions of their institutions. Awardees may not undertake substantial administrative responsibilities during the tenure period. Awardees may not engage in clinical practice, professional consultation, or other comparable activities, which do not relate to their research and teaching or are unnecessary for maintenance of their professional skills. Awardees may engage in scholarly writing, deliver occasional outside lectures, and serve in an advisory capacity to public or private nonprofit organizations, provided such activities are incidental in the amount of time involved and are within institutional policies.

Awards will be made to eligible institutions, for a single period of five years, on behalf of selected candidates. Each awardee will be directly responsible to the institution to which the award is made. Transfer of an award to other institutions requires prior approval of the Review Board. Special leave in another institution may be permitted if directly related to the purpose of the award.

Nomination: Candidates must be nominated. The nomination should take the form of a letter indicating the qualifications of the nominee. The nominator is also responsible for providing a bibliography and curriculum vitae of the candidate and for obtaining supporting letters from at least five to seven other scientists, a majority of whom should come from institutions other than the nominee's. Former Established Investigators of the Association may be renominated at the end of their current period of award.

Review of Candidates: All candidates will be evaluated in nation-wide competition with other candidates of comparable training and experience. Review will be made by an ad hoc external Review Board of five distinguished scientists, three of whom will be members of the Association's Committee on Research. A site visit can be included in the review process at the discretion of the Review Board.

NOVEMBER 15 DEADLINE FOR RESEARCH AND DEVELOPMENT AWARD APPLICATIONS

Applications for Research and Development Awards for the academic year 1975-1976, designed to assist exceptionally promising young investigators in their transition to the level of Established Investigators, *must be postmarked on or before November 15, 1974*. Notification of awards will be made by February 15.

The first and second highest rated applicants will receive the Elliott P. Joslin and Solomon A. Berson Research and Development Awards, respectively. The recipients of these awards may

have such designations for one year only, even though granted a Research and Development Award for a second year.

The following policies have been established by the Committee on Research:

Eligibility

Applicants must be members of the university-affiliated institutions within the United States and U.S. possessions. Applicants should have had three years of relevant research experience with publications; residency training is not considered the equivalent of research experience.

The Committee on Research will give special consideration to the following:

1. Intent of applicant to pursue a full-time academic career.
2. Tangible evidence of research performance.

Stipend

The stipend will be \$15,000 per year plus the customary fringe benefits of the sponsoring institution, providing the recipient of the award qualifies for such benefits. If the award is renewed for one year, there is an increase of \$1,000, and any aforementioned customary benefits of the sponsoring institution. Recipients are required to devote 90 per cent of their time to research activities; an institution may supplement the salary in accordance with the standards of the respective institution.

Payments will be made on the 15th of each month to the sponsoring institution.

Term

The awards will be made for one academic year, July 1 through June 30. Candidates may apply on a competing basis for a one-year-renewal period.

Submission of Applications

The sponsoring institution shall submit the application on behalf of the applicant. The application must be routed through the usual administrative channels of the sponsoring institution and must include endorsement of the applicant's preceptor and the department head. Except for renewal applications, an institution may submit only one application per year. A statement of the institution's plans for the applicant's future career must be included.

It is required that the institution submit details and precise amount of its fringe benefit program as applicable to a salary of \$15,000.

Eleven copies of the application, as well as all supporting material, *must be postmarked no later than November 15, 1974*. Notification of awards will be made by February 15.

The applicant's name and address should be written on the front of the enclosed postal card and returned with the application. It is necessary that this card accompany the application so that acknowledgment can be made to the applicant.

Institutional Overhead

It is understood that institutional expenses are *not* to be part of the award.

Travel and Relocation

Expenses of travel and relocation are *not* reimbursable.

Application Forms

Forms may be obtained from: Mr. Harry Hansen, Director of

ORGANIZATION SECTION

Business Operations, American Diabetes Association, Inc., 1 West 48th Street, New York, New York 10020.

NEW MEMBERS

The following were admitted to membership as of September 1, 1974.

Professional Members

DECEMBER 1 DEADLINE FOR LILLY AWARD APPLICATIONS

The 1975 Lilly Award will be given at the Thirty-fifth Annual Meeting of the American Diabetes Association. The following stipulations govern the contest for this annual award, which is supported by Eli Lilly and Company and consists of \$1,000 and a medal.

Purpose: To recognize demonstrated research in the field of diabetes, taking into consideration independence of thought and originality.

Eligibility: Any investigator in an appropriate field of work, closely related to diabetes, who is less than forty years of age on January 1 of the year in which the award is made. The research will not necessarily be judged in comparison with the work of more mature and experienced workers. The candidate should be a resident of the United States or Canada.

Nomination: Nominations for the award will be solicited from the members of the American Diabetes Association. Such nominations will be requested by repeated notices to be published in DIABETES. Names of nominees must be received before December 1 of the year preceding the award. The nomination should be accompanied by full information concerning the nominee's personality, training, and research work. Eleven copies of each item should be submitted. No member may send in more than one nomination. A list of the nominee's publications, if any, and eleven copies of the publication or manuscript for which the award is to be given should also accompany the nomination. The award may be given for work published during the year prior to December 1 of the year preceding the award. The nominee should be actively engaged at that time in the line of research for which the award is to be made.

Announcement: The name of the winner will be announced in DIABETES. The winner will be invited to present a paper on his work at the Annual Meeting. Papers considered for the award must be submitted with the idea that they will be published in whole or in part in DIABETES if found acceptable to the Editor and/or Editorial Board. If the Committee should decide that no outstanding work has been presented for this consideration, the award will not be made.

Award: In addition to the monetary award and medal, traveling expenses will be given to make it possible for the recipient to receive his award in person at the Annual Meeting.

NOVEMBER 17-23 IS DIABETES WEEK

Diabetes Week this year will be November 17-23, following the usual practice of observing Diabetes Week the week before Thanksgiving. Affiliate Associations and Committees on Diabetes of County and State Medical Societies are urged to note this date in making plans for their Public Education and Detection programs.

<i>Alabama</i>		
Taylor D. Caffey		Ozark
Jorge A. Pino		Birmingham
<i>California</i>		
Maj. Joseph S. Fisher		San Francisco (APO)
Vikram V. Kamdar		Pasadena
Alan A. Rosenbloom		Pico Rivera
Victor S. Schneider		San Francisco
Roy T. Young		Los Angeles
<i>Connecticut</i>		
Joseph L. Belsky		Danbury
<i>Florida</i>		
Barkley Beidleman		Pensacola
Jan T. Braaten		Miami
Herbert A. Burke, Jr.		Jacksonville
Michael S. Mishkin		Coral Springs
<i>Georgia</i>		
David E. Dalrymple		Atlanta
Bryan D. Noe		Atlanta
<i>Hawaii</i>		
Shozo Ogawa		Honolulu
<i>Illinois</i>		
Penny A. Persico		Chicago
Abdul Razzaq		Villa Park
Alfredo O. Santesteban		Rock Island
Abdul Sattar		Chicago
<i>Indiana</i>		
Guenter E. Ksionski		Elkhart
<i>Kansas</i>		
Joseph W. Hume		Wichita
<i>Maryland</i>		
John C. Babka		Bethesda
Pierre De Meyts		Bethesda
Robert J. Winter		Baltimore
<i>Massachusetts</i>		
Richard A. Cole		Boston
<i>Michigan</i>		
Arthur R. Levine		Detroit
Malcolm E. Williamson		Highland Park
<i>Minnesota</i>		
Robert C. McEvoy		Minneapolis
Michael W. Steffes		Minneapolis

ORGANIZATION SECTION

Allied Health Professional Members

<i>Missouri</i>	Richard Hellman Daniel G. Pipeleers	Kansas City St. Louis	<i>California</i> Judy A. Gery Lucy Schneidler Diana L. Van Dyke	Huntington Beach Palm Desert Palm Springs
<i>Nebraska</i>	Richard B. Tobin	Omaha	<i>Colorado</i> Judy Redeagle	Denver
<i>New Jersey</i>	Michael A. Bloom William B. Caskey	Pennsauken Trenton	<i>Illinois</i> Ronald J. Belusko Thomas G. Cavolina Sister Paulette L. O'Connell	Maywood Chicago Chicago
<i>New Mexico</i>	David S. Schade	Albuquerque	<i>Kansas</i> Margaret J. Sullivan	Wichita
<i>New York</i>	Mark Fingerhut Roque O. Polanco-Tello Joel H. Silver Mary F. Wheeler	Roslyn Heights Elmhurst New York Brooklyn	<i>Maryland</i> Ann C. Parry	Reisterstown
<i>North Carolina</i>	Amon L. Funderburk	Winston-Salem	<i>Missouri</i> Colleen A. Sheets	Columbia
<i>Oregon</i>	Charles F. Howard, Jr.	Beaverton	<i>Nebraska</i> Karan K. Dalgas	Omaha
<i>Pennsylvania</i>	Clyde F. Barker Kenneth H. Messner Ralph Schmeltz Gene F. Tutwiler	Philadelphia Hershey Pittsburgh Ft. Washington	<i>New Jersey</i> Patrick J. McMorrow, Jr.	Somerville
<i>Texas</i>	Ross P. Chiles John A. Menchaca Surendra K. Varma	Austin Lubbock Lubbock	<i>New York</i> Hilda W. Brett	West Hurley
<i>Virginia</i>	Carl H. Bivens	Roanoke	<i>North Carolina</i> Maribelle G. Connerat	Charlotte
<i>Washington</i>	Andrew P. Goldberg	Seattle	<i>Ohio</i> Mary A. Ignat	Toledo
<i>Wisconsin</i>	B.A. Gorsky	Milwaukee	<i>Tennessee</i> Carol A. Burnes	Nashville
OTHER COUNTRIES			<i>Texas</i> Mary T. Ellenbogen	San Antonio
<i>Brazil</i>	Antonio R. Chacra	Sao Paulo	<i>Wisconsin</i> Mariann C. Thompson	Kenosha
<i>Canada</i>	Aubie Angel Michel L. Lelievre	Toronto Ste-Foy		
<i>Mexico</i>	Alberto Solano	Guadalajara		
<i>Spain</i>	Francisco Jimenez-Pasqua	Madrid		
<i>Switzerland</i>	E. Rudolf Froesch	Zurich		

NEWS NOTES

ANNUAL MEETING OF THE AMERICAN DIETETIC ASSOCIATION

The Fifty-seventh Annual Meeting of The American Dietetic Association was held in Philadelphia, Pennsylvania, October 7-11. A symposium entitled "Advances in the Care of the Patient with Diabetes" was presented October 9 under the co-sponsorship of the American Diabetes Association. Ronald A. Arky, M.D., Cambridge, Massachusetts, was moderator. Following an introduction by Max Ellenberg, M.D., New York, President of the